Regorafenib - the efficacy and safety in the treatment of the advanced gastrointestinal stromal tumors after failure in treatment with imatynib and sorafenib - the summary and a disscussion of the phase III trial

The article discusses the international, multicentre, randomised, placebo-controlled phase III trial, published in 2012, performed in patients with metastatic or unresectable gastrointestinal stromal tumor progressing after the failure of at least imatinib and sunitinib. The trial was conducted in order to assess the efficacy and safety of regorafenib - the newest, oral, multiknase inhibitor, and resulted in the registration of that drug as a third line treatment in patients with drug-resistant GIST. The article focuses on the difficulties related to the treatment of advanced or metastatic GIST, summarizing the newest research and clinical implications of the results.